Search
Page tools
click to adjust font size
Social Bookmarks
Bayer HealthCare Links
Financial Report
Company Brochure
Clinical trials
Information about clinical studies is available at database of
Press portal
Bayer Links
Copyright ©
Bayer HealthCare AG
News
-
2010-08-31 | Thrombosis
Bayer´s Rivaroxaban Successfully Meets Primary Efficacy Outcome and Demonstrates Similar Safety to Standard Therapy in Phase III EINSTEIN-DVT Non-Inferiority Study
2010-08-31 | Thrombosis
Bayer´s Rivaroxaban Successfully Meets Primary Efficacy Outcome and Demonstrates Similar Safety to Standard Therapy in Phase III EINSTEIN-DVT Non-Inferiority Study
Results from EINSTEIN-DVT Study Presented at European Society of Cardiology Congress 2010 more
-
2010-08-30 | Worldnews
Intendis and KYTHERA Enter Licensing and Development Agreement on Adipolytic Agent for Aesthetic Dermatology Use
2010-08-30 | Worldnews
Intendis and KYTHERA Enter Licensing and Development Agreement on Adipolytic Agent for Aesthetic Dermatology Use
Bayer’s dermatology subsidiary Intendis prepares to enter aesthetics segment / Joint development of first-in-class injectable drug for minimally invasive facial fat reduction more
-
2010-08-04 | Thrombosis
Bayer’s Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study
2010-08-04 | Thrombosis
Bayer’s Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study
Rivaroxaban shows superiority to standard therapy in net clinical benefit, a secondary endpoint of the study / Rivaroxaban well tolerated in this long-term trial / Full data set to be presented at Hot Line Session at ESC 2010 more
-
2010-08-04 | Worldnews
FDA Accepts New Drug Application for Gadovist® 1.0 Injection in Magnetic Resonance Imaging
2010-08-04 | Worldnews
FDA Accepts New Drug Application for Gadovist® 1.0 Injection in Magnetic Resonance Imaging
Bayer Schering Pharma AG, Berlin, Germany, announced today that the Food and Drug Administration has accepted for filing a New Drug Application to the U.S. for gadobutrol injection, a gadolinium-based contrast agent for magnetic resonance imaging more
-
2010-07-29 | Bayer HealthCare
Bayer increases sales and earnings in the second quarter
2010-07-29 | Bayer HealthCare
Bayer increases sales and earnings in the second quarter
Sales grow by 14.6 percent to EUR 9,179 million / EBITDA before special items up 8.6 percent to EUR 1,917 million / Core earnings per share increase by 9.5 percent to EUR 1.15 / Investing in the future: research and development expenses in 2010 to reach a new high of approximately EUR 3.1 billion / Group outlook confirmed for 2010 more
